Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)

• Status: Recruiting
• Trial end date: 2024-12-01

Summary

This is a randomized, multicenter, double-blind, Phase 3 study of efficacy and safety of BCD-100 plus platinum-based chemotherapy with and without bevacizumab versus placebo plus platinum-based chemotherapy with and without bevacizumab

• Phase: Phase 3

Details

• Lead Sponsor: Biocad
• Treatments: Bevacizumab; Carboplatin; Paclitaxel